| Identification | Back Directory | [Name]
ACHN 975 | [CAS]
1410809-36-7 | [Synonyms]
ACHN 975
nii-48cet2EN53
N-((S)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(((1R,2R)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diynyl)benzamide
Benzamide, N-[(1S)-2-amino-1-[(hydroxyamino)carbonyl]-2-methylpropyl]-4-[4-[(1R,2R)-2-(hydroxymethyl)cyclopropyl]-1,3-butadiyn-1-yl]- | [Molecular Formula]
C20H23N3O4 | [MDL Number]
MFCD29991590 | [MOL File]
1410809-36-7.mol | [Molecular Weight]
369.41 |
| Hazard Information | Back Directory | [Uses]
ACHN 975 inhibits LpxC, an essential enzyme in the Gram-negative lipid A biosynthetic pathway, and is the first LpxC inhibitor to enter human clinical trials. | [in vivo]
ACHN-975 (intraperitoneal administration; 5-30?mg/kg; single dose) leads to a steady reduction in bacterial titers in the first 4?h following treatment for all dosing groups. The sampling shows that the level of free drug in this model drops below the ACHN-975 MIC for this isolate (0.25?μg/ml) by 2?h after treatment with the 10 mg/kg dose and by 4?h after treatment with the 30 mg/kg dose[2]. | Animal Model: | Neutropenic mouse thigh model with?P. aeruginosa?ATCC 27853[2] | | Dosage: | 5-30?mg/kg | | Administration: | Intraperitoneal administration; single dose | | Result: | Had a bactericidal activity and was against the?P. aeruginosa?ATCC 27853 strain in vivo. |
|
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|